FDA Panel Endorses Arena's New Obesity Drug
In an 18-4 vote with one abstention, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee said the available data supported approval of the drug. If the agency takes up the committee’s recommendation, lorcaserin could become the first obesity drug approved by the FDA since Roche Holding AG's Xenical in 1999.
"The advisory committee's positive...
To view the full article, register now.